Safety and efficacy of a long‐acting liposomal formulation of plasma‐derived factor VIII in haemophilia A patients

School of Biological Sciences, University of the Punjab, Lahore, Pakistan, Department of Haematology, Great Ormond Street Hospital, Department of Medicine, University College London, London, Paediatric Haematology/Oncology Unit, John Radcliffe Hospital, Children’s Hospital, Oxford, UK and Paediatric Haematology Unit, Department of Paediatrics, Medical School of Gazi University, Ankara, Turkey E-mail: rosemary.gale@ucl.ac.uk

[1]  P. Rosenberg,et al.  Extended spectrum of human glucose-6-phosphatase catalytic subunit 3 deficiency: novel genotypes and phenotypic variability in severe congenital neutropenia. , 2012, The Journal of pediatrics.

[2]  C. Klein,et al.  G6PC3 mutations are associated with a major defect of glycosylation: a novel mechanism for neutrophil dysfunction. , 2011, Glycobiology.

[3]  W. Newman,et al.  Variability of bone marrow morphology in G6PC3 mutations: Is there a genotype–phenotype correlation or age‐dependent relationship? , 2011, American journal of hematology.

[4]  Y. Crow,et al.  Further delineation of the phenotype of severe congenital neutropenia type 4 due to mutations in G6PC3 , 2011, European Journal of Human Genetics.

[5]  S. Paul,et al.  Severe congenital neutropenia resulting from G6PC3 deficiency with increased neutrophil CXCR4 expression and myelokathexis. , 2010, Blood.

[6]  M. Ballmaier,et al.  Digenic mutations in severe congenital neutropenia , 2010, Haematologica.

[7]  M. Morfini,et al.  Efficacy and safety of secondary prophylactic vs. on‐demand sucrose‐formulated recombinant factor VIII treatment in adults with severe hemophilia A: results from a 13‐month crossover study , 2010, Journal of thrombosis and haemostasis : JTH.

[8]  Bodo Grimbacher,et al.  A syndrome with congenital neutropenia and mutations in G6PC3. , 2009, The New England journal of medicine.

[9]  K. Fischer,et al.  Efficacy assessment of a new clotting factor concentrate in haemophilia A patients, including prophylactic treatment , 2009, Haemophilia : the official journal of the World Federation of Hemophilia.

[10]  D. Link,et al.  Prevalence of mutations in ELANE, GFI1, HAX1, SBDS, WAS and G6PC3 in patients with severe congenital neutropenia , 2009, British journal of haematology.

[11]  M. Baru,et al.  Enhancement of haemostatic efficacy of plasma‐derived FVIII by formulation with PEGylated liposomes , 2009, Haemophilia : the official journal of the World Federation of Hemophilia.

[12]  J. Yagüe,et al.  A novel G6PC3 homozygous 1-bp deletion as a cause of severe congenital neutropenia. , 2009, Blood.

[13]  Asim Khwaja,et al.  Homozygous HAX1 mutations in severe congenital neutropenia patients with sporadic disease: a novel mutation in two unrelated British kindreds , 2009, British journal of haematology.

[14]  Ji-Yun Kim,et al.  Enhanced efficacy of recombinant FVIII in noncovalent complex with PEGylated liposome in hemophilia A mice. , 2007, Blood.

[15]  J. Spira,et al.  Evaluation of liposomal dose in recombinant factor VIII reconstituted with pegylated liposomes for the treatment of patients with severe haemophilia A , 2008, Thrombosis and Haemostasis.

[16]  H. Stass,et al.  Safety and pharmacokinetics of a recombinant factor VIII with pegylated liposomes in severe hemophilia A. , 2008, Journal of thrombosis and haemostasis : JTH.

[17]  A. Shapiro.  Anti-hemophilic factor (recombinant), plasma/albumin-free method (octocog-alpha; ADVATE®) in the management of hemophilia A , 2007, Vascular health and risk management.

[18]  Alan R. Cohen,et al.  Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. , 2007, The New England journal of medicine.

[19]  J. Spira,et al.  Prolonged bleeding-free period following prophylactic infusion of recombinant factor VIII reconstituted with pegylated liposomes. , 2006, Blood.

[20]  Yechezkel Barenholz,et al.  Factor VIII efficient and specific non-covalent binding to PEGylated liposomes enables prolongation of its circulation time and haemostatic efficacy , 2005, Thrombosis and Haemostasis.